These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11686021)

  • 1. Adoptive immunotherapy of CNS malignancies.
    Plautz GE; Shu S
    Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE; Touhalisky JE; Shu S
    Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous natural killer cell therapy for human recurrent malignant glioma.
    Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
    Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y; Black KL; Yu JS
    Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of local immunoresistance in glioma.
    Albesiano E; Han JE; Lim M
    Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
    Janelidze S; Bexell D; Badn W; Darabi A; Smith KE; Fritzell S; Gunnarsson S; Milos P; Bengzon J; Salford LG; Siesjö P; Visse E
    J Immunother; 2009; 32(6):593-601. PubMed ID: 19483650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
    Lee Y; Bigner DD
    Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring immune responses after glioma vaccine immunotherapy.
    Jian B; Yang I; Parsa AT
    Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
    J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
    Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
    Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
    de Vleeschouwer S; Rapp M; Sorg RV; Steiger HJ; Stummer W; van Gool S; Sabel M
    Neurosurgery; 2006 Nov; 59(5):988-99; discussioin 999-1000. PubMed ID: 17143233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dendritic cell therapy for malignant glioma].
    Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
    No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for human glioma: innovative approaches and recent results.
    Hussain SF; Heimberger AB
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
    Kubo O; Takakura K
    Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.